In-vivo Evaluation of Clastogenic and Aneugenic potential of Palmitoyl-mono-Ethanolamide (PEA)

Narendra S Deshmukh1, Kanhere Jaideep1, Sedatrul Muntha2, Silma Subah2, Paul R Clayton2

2Gencor Pacific Ltd, Unit 3, 1st Floor, Discovery Bay North Plaza, Discovery Bay, Hong Kong.


Keywords
Palmitoyl-mono-Ethanolamide, Clastogenicity, Aneugenicity.

Introduction
The pharmacological properties of the autacoid PEA are well documented, with over 350 papers describing its anti-inflammatory, anti-viral, analgesic, antiepileptic and neuroprotective effects [1]. PEA’s actions at CB1, GPR55 [2,3] and other receptors in the central nervous system have been shown to modulate excitatory glutamatergic signalling and dopaminergic activity via the mesolimbic pathway, with therapeutic relevance for cognition, contextual memory and emotional regulation [3].

This research has led to a proliferation of non-licensed PEA supplements, which raises safety concerns because the available safety data is rather limited. The most relevant research in this area, including rodent [4,5] and dog studies [6,7] is undoubtedly helpful, but important gaps in PEA’s safety profile remain.

The Nestmann paper [4] includes the Ames test, an in vitro mammalian cell micronucleus test and acute, 14- and 90-day oral toxicity studies in rats. There was no evidence of cytotoxicity or genotoxicity. The acute oral LD50 was >2,000 mg/kg body weight, and the 14-day and 90-day sub-chronic oral toxicity studies revealed no treatment-related adverse events. The no-observed-adverse-effect level (NOAEL) of micronized PEA was 1,000 mg/kg body weight /d, the highest dose tested. Deshmukh et al. [5] demonstrated a NOAEL for maternal toxicity, embryotoxicity, fetotoxicity, and teratogenicity >1,000 mg/kg body weight/d, equivalent to a human dose of greater than 9.7 g/d.

No significant or dose-related adverse effects of PEA have been reported in animal models [4-7] or in human studies [8,9] to date. However, and especially concerning given the rapid commercial development of PEA, there is not yet sufficient evidence regarding possible genotoxicity.

The genotoxicity testing strategy in the EFSA Scientific Committee opinion [10] is designed to investigate the genotoxic potential of substances through the detection of gene mutations, structural chromosomal aberrations and numerical chromosomal aberrations. The testing strategy is a stepwise approach, beginning with a basic battery of in vitro tests, comprising of a bacterial reverse mutation assay [Ames Test, OECD TG 471, end-point: gene mutations]; and an in vitro mammalian cell micronucleus (MN) test (OECD TG 487, endpoints: clastogenicity and aneugenicity) [11].

Apart from the two in vitro mutagenicity tests described by Nestmann [4], the possible clastogenic and aneugenic properties of PEA have not been adequately studied; and no in vivo micronucleus test has been reported in the literature. An in vivo study was therefore initiated to confirm and substantiate the in vitro PEA studies.

Our study evaluated the genetic toxicology of PEA in terms of clastogenicity and aneugenicity in an erythrocyte micronucleus test in mice dosed orally at of 2000 mg/kg body weight. The study was conducted in compliance with the Organization for economic Cooperation and Development (OECD) test guideline number 474 and the OECD principles of GLP; and carried out at the OECD GLP certified test facility of Intox Pvt. Ltd., Pune, India.

Methods
The In vivo Micronucleus Test for Palmitic Acid Mono Ethanolamide (CAS no. 544-31-0) was performed in mouse peripheral blood cells. A white crystalline powder of PEA,
manufactured by Shilpa Medicare Ltd., Raichur, Karnataka, India in April 2020 (Batch Number PML220002G) with the active ingredient to be >99% w/w was supplied by Gencor Pacific Limited, Hong Kong, along with its certificate of analysis. The PEA was uniformly suspended in analytical grade water by using Tween 80 as a wetting agent at 0.2% w/v. The dosing formulations were prepared immediately prior to administration, using the same method that was validated for ensuring homogeneity in previous GLP studies performed at Intox, which had demonstrated that PEA was stable in such formulation for 48 h at 22 ± 3 ºC.

Animal Welfare
The study was performed as per the Study Plan approved by the Institutional Animal Ethics Committee. The meeting was held on 12 January, 2022 and Form B12/21007 for the present study was approved. The relevant certificate of approval has been maintained at the Test Facility.

Selection of Test Doses
A preliminary study was performed in the same laboratory (Intox Pvt Ltd), using the same species, strain, sex, and treatment regimen to be used in the main study, as required by the OED TG 474. Six Swiss albino mice, three male and three female, bred and reared at Intox Pvt Ltd, were dosed with PEA by oral gavage for two consecutive days at a dose of 2000 mg/kg body weight. The only adverse effect of treatment was transient hypoactivity in mice of both sexes following the second dose of PEA.

Since there was no previous evidence of observable significant toxicity at 2000 mg/kg body weight, identified as a ‘limit dose’ by the OECD TG 474, and there was no sex-difference observed in the manifestation of the signs of hypoactivity, it was decided to conduct the main study as a ‘Limit Test’ at a single dose level at the ‘limit dose’ and that only in male mice.

Main Study
Five male Swiss albino mice, bred and reared at Intox Pvt Ltd, were administered with PEA, formulated in analytical grade water with 0.2% Tween 80, by oral gavage for two consecutive days at a dose of 2000 mg/kg body weight. A concurrent vehicle control group of five male mice was administered with 10 mL/kg of analytical grade water with 0.2% Tween 80, while another concurrent positive control group of five male mice was administered with cyclophosphamide monohydrate at the dose of 15 mg/kg body weight. The mice were treated for two consecutive days, at an interval of about 24 hours.

All mice were observed for signs of toxicity following the treatment and were sacrificed at 45 hours after the last treatment. The animals were monitored for mortality, clinical signs and body weight. Blood from each mouse was collected, fixed and subsequently stained with anti-mouse CD71 and anti-rodent CD61 antibodies. About 21,000 polychromatic erythrocytes (PCEs, i.e. immature erythrocytes) per animal were examined using a flow cytometer to detect the incidence of micronucleated PCEs (MN-PCEs). In addition, a proportion of immature erythrocytes was assessed for each animal as a measure of potential toxicity.

Results
Survival, Clinical Signs, Body Weights
All mice survived treatment with PEA. Signs of transient hypoactivity were observed in three mice treated with PEA following its second dose at 2000 mg/kg body weight. PEA did not adversely affect the body weight of any of the treated mice.

Incidence of PCEs (%)
The incidence of PCEs (CD-71 positive immature erythrocytes) in mice treated with PEA was 1.34 ± 0.19%. This was comparable (p>0.05) with the PCE incidence of 1.49 ± 0.16 % in the vehicle control group. In contrast, in mice treated with positive control item Cyclophosphamide monohydrate, there was a statistically significant (p<0.05) reduction in the incidence of PCEs, with the mean found to be 0.76 ± 0.07%. This was 49% lower than that of the vehicle control group (Table 1).

Incidence of MN-PCEs (%)
The incidence of micronucleated PCEs (MN-PCEs, mean ± SD) in mice treated with two doses of PEA at 2000 mg/kg was 0.16 ± 0.01%, while that in the vehicle control group was 0.14 ± 0.02%. The means were statistically comparable (p>0.05).

The incidence of MN-PCEs in mice treated with the positive control item Cyclophosphamide monohydrate was 0.87 ± 0.07%.

Table 1: Proportion of Immature Erythrocytes and Micronucleated Erythrocytes.

<table>
<thead>
<tr>
<th>Group</th>
<th>Dose (per kg bwt)</th>
<th>Description</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle Control (Analytical grade water with 0.2% Tween 80)</td>
<td>10 mL</td>
<td>Mean 1.49 ± SD 0.16</td>
<td>% PCE 0.14 ± SD 0.02</td>
</tr>
<tr>
<td>Treatment (PEA – Palmitic Acid Mono Ethanolamide)</td>
<td>2000 mg</td>
<td>Mean 1.34 ± SD 0.19</td>
<td>% MN-PCE 0.16 ± SD 0.01</td>
</tr>
<tr>
<td>Positive Control (Cyclophosphamide monohydrate)</td>
<td>15 mg</td>
<td>Mean 0.76 ± SD 0.07</td>
<td>% PCE 0.87 ± SD 0.07</td>
</tr>
</tbody>
</table>

PCE – Polychromatic (immature) erythrocytes; MN-PCE – Micronucleated PCEs; Sampling time: 45 h after last dose

*mean differs from the vehicle control mean statistically at p<0.05.
which was significantly lower (p<0.05) than the control mean (Table 1).

**Discussion**

Two daily consecutive treatments with PEA in mice at the limit dose of 2000 mg/kg body weight did not cause death or any overt signs of toxicity. The transient hypoactivity observed following the second dose was consistent with findings observed in the preliminary studies. The oral LD50 of PEA in mice was previously reported to be > 4 g/kg body weight (18) and the findings of the present study were consistent with this.

The incidence of PCEs in mice treated with PEA was comparable (p>0.05) with the PCE incidence in the vehicle control group, indicating an absence of haemopoietic toxicity. The positive Cyclophosphamide monohydrate controls were as expected.

The incidence of micronucleated immature erythrocytes (% MN-PCE) in the peripheral blood of treated mice matched the vehicle control group (p>0.05), indicating a null effect. Again, the positive Cyclophosphamide monohydrate controls were as expected, confirming the sensitivity of the test system and validity of the assay.

As PEA is increasingly being used in the supplement space, which is neither supervised nor adequately monitored, and by consumer groups which include children and pregnant women, the issue of potential genotoxicity was considered as a matter of urgency. This is not an abstract concern; natural supplements including herbs have been previously identified as having clastogenic and aneugenic properties [ie 12,13], and regulatory authorities have been compelled to respond appropriately.

The mammalian erythrocyte MN Test (OECD TG 474), covering the endpoints of structural and numerical chromosomal aberrations of erythroblasts, is the only validated assay for the in vivo follow-up of in vitro aneugenic compounds. The experimental protocol was standardised to evaluate MN formation in young erythrocytes (polychromatic) sampled in bone marrow and/or reticulocytes in peripheral blood cells of rodents. Newly formed micronucleated erythrocytes are identified and quantitated by staining followed by visual microscopic scoring. With positive results, kinetochore staining or FISH with a pan-centromeric probe is not mandatory to confirm aneugenesis in vivo. Automated analysis of micronuclei on cell suspensions using flow cytometry allows scoring of a large number of cells, reducing scorer subjectivity and increasing the statistical power.

Unmicronised, micronised, and ultra-micronised PEA formulations are absorbed following oral administration, with measurements of PEA in blood plasma in rats [14] and in humans [9,15]. Exposure of bone marrow to PEA has therefore been established. While the earlier in vitro mutagenicity studies provide some reassurance of absence of genotoxicity, our in vivo findings extend and confirm PEA’s safety profile.

**Conclusion**

Under the given conditions of this mammalian (in vivo) erythrocyte micronucleus test in mouse peripheral blood, the test item Palmitoyl Mono-Ethanolamide (PEA) is non-clastogenic and non-aneugenic.

**References**


